KCNH2 and tuberculosis: Based on that data, compounds 8 and 46 were selected due to their lower MICs than bedaquiline against clinical isolates of M.tb, efficacy demonstrated against murine TB at lower exposures than bedaquiline, lower potency against hERG, predicted higher human clearance, and an acceptable safety margin, based on the safe exposure in rats compared to the efficacious exposure in mice.